[Edaily Reporter Lee So-Hyun ] Naver (NAVER(035420)) has signed a $9 billion artificial intelligence (AI) factory computing infrastructure contract with global alternative investment firm Brookfield and finalized the specific business structure.
Naver announced on the 27th through a corrected disclosure regarding “Future Business and Management Plans” that the computing infrastructure contract had been finalized. The $9 billion computing service infrastructure required to build the AI Factory will be established through “Asset Co. (tentative name),” an asset-holding company to be formed by an investment vehicle of the Brookfield AI Infrastructure Fund.
On September 3, Bruce Flat (second from left), Chairman of Brookfield Corporation, and Park Jun-woo, CEO of Brookfield Korea, visited Naver 1784 in Seongnam, Gyeonggi Province, where they held follow-up discussions on the global AI Factory construction project with Naver Chairman Lee Hae-jin and Naver CEO Choi Soo-yeon. (Photo: Naver) Naver Cloud plans to provide AI data center services to customers by procuring GPU-based computing resources from Asset Co. as a service (GPUaaS).
Notably, Asset—which is 100% owned by a Brookfield special purpose acquisition company—is expected to be consolidated as a subsidiary of Naver in accordance with Korean International Financial Reporting Standards (K-IFRS).
In collaboration with NVIDIA, Naver plans to build AI factory infrastructure with a capacity of 55 megawatts (MW) in the first half of 2027 and a cumulative capacity of 200 MW by 2028, with long-term plans to expand to the gigawatt (GW) level.
“Technological capability does not automatically guarantee funding.” This is a common saying in the energy and climate tech ecosystem. This is because technology development takes a long time, and com…
The domestic department store industry is actively working to attract Gen Z customers (born in the mid-to-late 1990s through the early 2000s). They are attracting young people through pop-up stores fe…
ST Pharm Co., Ltd.(237690)continued to post year-over-year revenue growth in the third quarter of this year, driven by its oligonucleotide (oligo) commercialization project and expanded sales in its s…
